Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — IPO Roadshow (February 2023)
27 slides from Maia Biotechnology's IPO roadshow presentation, Feb 13, 2023
Slide 1: Telomere Targeting Immunotherapies for Cancer
[Company Logo] TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA February 2023
Slide 2: Free Writing Prospectus
FREE WRITING PROSPECTUS [Company Logo] This presentation highlights basic information about us and the proposed offering. Because it is a summary, it does not contain all of the information that you should consider before investing. We have filed a registration statement (including a prospectus) wit
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Company Logo All statements in this presentation, other than those relating to historical facts, are "forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; statements
Slide 4: Investment Overview
INVESTMENT OVERVIEW Company Logo Telomere-Targeting Agents: THIO in clinic Advancing pipeline Efficacy Safety FDA: 2 Orphan Drug Designations REGN: Supply Agreement Phase 2 THIO-101 trial in NSCLC underway Enrolling in AUS and EU On track to open sites in US in 2023 Upcoming Milestones: Safety, ORR,
Slide 5: Robust Pipeline
ROBUST PIPELINE Company Logo PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COLLABORATION & RIGHTS THIO Telomere targeting agent THIO-101 NSCLC THIO Libtayo Ph 2 Enrolling July 2022 THIO-102 CRC, HCC, SCLC, ST THIO CPI Ph 2 Planning THIO-103 Confirmatory/Definitive Approval Ph 2/3 Planning 2 nd Generation Telo
Slide 6: Science Overview
SCIENCE OVERVIEW Company Logo THIO (6-thio-dG) Telomere Targeting Agent Small molecule Eligible for NCE marketing exclusivity Dual MoA: telomere targeting + immunogenic CR with No Recurrence in vivo in Lung, Colorectal, Liver, Melanoma, Brain Cancer (GBM, DIPG, MB), etc Two FDA Orphan Drug Designati
Slide 7: Mission and Approach
MISSION AND APPROACH Company Logo 7
Slide 8: Cancer is the most dominant age-related disease
Company Logo Cancer is the most dominant age-related disease Population aged >80 expected to triple by 2050 142 million 2020 426 million 2050 At age 90: 40% will be diagnosed 20% will die of it 8
Slide 9: THIO is the only direct telomere targeting agent in clinical development
Company Logo THIO is the only direct telomere targeting agent currently in clinical development 9
Slide 10: THIO - Checkpoint Inhibitors
THIO - CHECKPOINT INHIBITORS Company Logo THIO Company Logo Nucleus Cell Telomere Chromosome Tumor cell Death PD-L1 Anti-PD-L1 Anti-PD-1 PD-1 T cell CPIs THIO has a dual MoA: 1 Telomere targeting 2 Immunogenic effect 3 Checkpoint Inhibitors THIO GGGGTT CCCCAA CCCCAA LIBTAYO KEYTRUDA TECENTRIQ OPDIVO
Slide 11: Regeneron Agreement
REGENERON AGREEMENT Company Logo Company Logo & REGENERON MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinicl Trail Evaluating THIO in Sequential Administration with Libtayo® (cemiplimab) in Advanced Non-Small Cell Lung Cancer 11
Slide 12: THIO: Clinical Development Strategy
Company Logo THIO: CLINICAL DEVELOPMENT STRATEGY 12
Slide 13: Clinical Development Overview
CLINICAL DEVELOPMENT OVERVIEW Company Logo THIO-101 Ph 2 trial THIO + LIBTAYO® Go-to-Market NSCLC REGN supply agreement Enrolling at multiple sites in AUS and EU (2022) File US IND and commence enrolling in US in 2023 Select optimal dose and expand File for accelerated approval (2025) THIO-102 Ph 2
Slide 14: THIO-101 Trial (Ongoing)
THIO-101 TRIAL (ONGOING) Company Logo A Multicenter, Open-Label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with LIBTAYO® (cemiplimab) Part A: Safety Part B: Efficacy / Safety / Dose Selection Part C*: Every 3 Weeks NSCL C 2L+ THIO 360mg Immune Act
Slide 15: THIO-101 Trial Milestones
THIO-101 TRIAL milestones Company Logo Catalyst Timing Current SoC (Chemo) Safety Q1 2023 72-79% Grd 3-4 Preliminary Efficacy (ORR) 2023 11-23% DoR, PFS 2024 4-4.5m OS 2025 8.1-10.5m Line Chart Tumor Volume (mm3) 1000 900 800 700 600 500 400 300 200 100 0 Control anti-PD-L1 THIO THIO anti-PD-L1 No c
Slide 16: Biomarker – TIFs
BIOMARKER – TIFs Company Logo (Telomere dysfunction Induced Foci) Confocal microscopy image of LLC cell nucleus after treatment with THIO Quantification of TIFs induced in LLC cell by 3 µM of THIO DAPI γH2AX Tel C 10.0 µM Bar Chart Number of TIFS per cell TIFS 10 5 0 -5 ctrl 24hrs 48hrs 72hrs TIFs i
Slide 17: THIO-102 Trial (Planned)
THIO-102 Trial (Planned) Company Logo A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1 in Patients with Telomerase (+) Tumors Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 2 Baskets Umbrella Arms Cohort
Slide 18: THIO-102 Trial - Colorectal
THIO-102 TRIAL-COLORECTAL Company Logo Catalyst Timing Current SoC (Chemo) Safety ORR DoR, PFS OS 2024 2024 2025 2026 50-60% Grd ≥ 3 1-1.6% 1.9-2.0m 6.4-7.2m 700 600 500 400 300 200 100 0 0 10 20 30 40 50 60 70 80 90 100 100% CR Control Anti-PD-L1 THIO THIO anti-PD-L1 Tumor Volume (mm3) Days After T
Slide 19: THIO-102 Trial SCLC & HCC
THIO-102 TRIAL SCLC & HCC Company Logo Tumor Volume (mm3) 1250 1000 750 H2081 SCLC Control 6-thio-dG+pembro Pembrolizumab 500 250 0 0 5 10 15 20 25 30 Days after HCC33N tumor inoculation Tumor Volume(mm 3 ) 1750 1500 1250 1000 750 500 250 0 Control 6-thio-dg(5mg/kg) 6-thio-dg+IR IR(10Gy)+anti_PDL1 I
Slide 20: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY Company Logo Goal: New Chemical Entity (NCE) Marketing Exclusivity THIO has never been previously approved by the FDA for commercialization Robust exclusivity US: 7 years; EU, Japan, other markets: 10 years Robust and Growing Patent Portfolio for THIO 1 issued U
Slide 21: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Company Logo Vlad Vitoc, MD, MBA Founder, Chairman, and Chief Executive 22+ years in Pharma/Biotech: Commercial, Medical, 12 compounds launched across 20+ tumor types Leadership roles at Bayer (Nexavar), Astellas (Tarceva, Xtandi), Cephalon (Treanda), Novartis (Zometa), a
Slide 22: Capitalization Table & Cash Balance
CAPITALIZATION TABLE & CASH BALANCE Capitalization Table (as of 12/31.2002) Company Logo Common stock 10,955,904 Option (WAEP: $2.55) 1 6,545,628 Warrants (WAEP: $6 .04) 796,985 Fully Diluted Shares Outstandingn18,298,517 Cash Balance of $10.95 million (as of 12/31/2022) 1 4,282,309 options held by
Slide 23: Investment Opportunity
INVESTMENT OPPORTUNITY 23 Company Logo
Slide 24: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY Company Logo Developing agents for the top tumor types markets globally NSCLC #1 WW Mortality: 1.6M in 2021 Sales: $23B in 2021 CRC #2 WW Mortality: 943,000 in 2021 Sales: $8B in 2021 $34.0 B CPIs Market $34.0B 5 CPIs approved for NSCLC $12B of $23B total NSCLC drug sa
Slide 25: Comparable Companies
COMPARABLE COMPANIES Company Logo MAIA BIOTECHNOLOGY MIRATI THERAPEUTICS Zentalis IOVANCE BIOTECHNOLOGY KURA ONCOLOGY Turning Point Therapeutics $50M $3.13B $1.40B $1.28B $0.94B $4.1B On June 3, 2022, Bristol Myers Squibb announced the acquisition of Turning Point Therapeutics in an all-cash transac
Slide 26: Multiple Value-Driving Milestones
MULTIPLE VALUE-DRIVING MILESTONES Company Logo Major inflection points Potential Accelerated Approval in US Filing for US approval FDA ODDs HCC & SCLC THIO-101 Initiated NSCLC Ph 2 (AUS, EU) THIO-101 Safety Data THIO-101 IND filing THIO-101 Prelim Efficacy ORR THIO-102 Ph 2 CRC, HCC, SCLC, ST THIO-1
Slide 27: MAIA Biotechnology Listed
MAIA BIOTECHNOLOGY LISTED MAIA Company Logo NYSE: MAIA July 28, 2022 27